Strata Critical Medical Reports Strong Q4, Raises 2026 Revenue & EBITDA Guidance
SRTA has more than doubled off its 52-week low of $2.35.
Summary
Strata Critical Medical announced robust fourth-quarter 2025 financial results, including significant revenue and Adjusted EBITDA growth, and raised its full-year 2026 guidance.
Key Events · Earnings and Guidance · SRTA
-
Strong Q4 2025 Performance
Total revenue increased 83.5% year-over-year to $66.8 million, with Logistics revenue growing 35.3%. Adjusted EBITDA surged 547% to $7.0 million.
-
Full-Year 2025 Exceeds Guidance
Full-year 2025 Adjusted EBITDA of $14.1 million surpassed the high end of the company's guidance range.
-
Raised 2026 Financial Outlook
The company increased its full-year 2026 revenue guidance to $260-$275 million and Adjusted EBITDA guidance to $29-$33 million.
-
Enhanced Liquidity and Strategic Growth
Strata closed a new $30 million asset-backed credit facility and continues to expand its organ recovery platform and aircraft fleet, supporting future growth initiatives.
Analysis · SRTA · Industrial Applications And Services
Strata Critical Medical demonstrated strong operational momentum with an 83.5% year-over-year increase in Q4 revenue and a 547% surge in Adjusted EBITDA, exceeding prior guidance. The raised 2026 revenue and Adjusted EBITDA outlook, coupled with the successful integration of the Keystone acquisition and a new $30 million credit facility, signals continued growth and improved financial health. Investors should view this as a strong indicator of the company's execution and future potential in the critical medical logistics sector.
At the time of this filing, SRTA was trading at $4.84 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $387.8M. The 52-week trading range was $2.35 to $6.02. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.